Thompson Siegel & Walmsley’s PDL BioPharma, Inc. PDLI Stock Holding History

Thompson Siegel & Walmsley’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,000	Closed	-$7K	–	940
2016 Q3	$7K	Hold	2,000	–	–	﹤0.01%	664
2016 Q2	$6K	Hold	2,000	–	–	﹤0.01%	673
2016 Q1	$7K	Hold	2,000	–	–	﹤0.01%	631
2015 Q4	$7K	Hold	2,000	–	–	﹤0.01%	638
2015 Q3	$10K	Hold	2,000	–	–	﹤0.01%	615
2015 Q2	$13K	Hold	2,000	–	–	﹤0.01%	597
2015 Q1	$14K	Hold	2,000	–	–	﹤0.01%	598
2014 Q4	$15K	Hold	2,000	–	–	﹤0.01%	591
2014 Q3	$15K	Hold	2,000	–	–	﹤0.01%	590
2014 Q2	$19K	Hold	2,000	–	–	﹤0.01%	555
2014 Q1	$17K	Hold	2,000	–	–	﹤0.01%	557
2013 Q4	$17K	Hold	2,000	–	–	﹤0.01%	538
2013 Q3	$16K	Hold	2,000	–	–	﹤0.01%	540
2013 Q2	$15K	Buy	+2,000	New	+$15.6K	﹤0.01%	550

Other funds holding PDLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Thompson Siegel & Walmsley's PDLI Position: Q4 2016 in Review

Thompson Siegel & Walmsley sold out of PDL BioPharma, Inc. (PDLI) in Q4 2016, closing a stake of 2,000 shares — an estimated $7K sold.

Thompson Siegel & Walmsley first reported a position in PDLI in Q2 2013 and held it in 14 quarters. The position peaked at $19K in Q2 2014. 190 funds tracked by Wall St. Rank hold PDLI as of Q4 2016.

Thompson Siegel & Walmsley reported no remaining PDL BioPharma, Inc. position as of Q4 2016 after selling out during the quarter.
Thompson Siegel & Walmsley sold 2,000 PDL BioPharma, Inc. shares in Q4 2016, an estimated $7K.
Thompson Siegel & Walmsley first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 14 quarters.
Thompson Siegel & Walmsley's PDL BioPharma, Inc. position peaked at $19K in Q2 2014.
190 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2016.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2016, filed 13 Feb 2017.